Amlin (LON: AML)‘s stock had its “underperform” rating reiterated by equities research analysts at Credit Suisse in a research note issued to investors on Monday. They currently have a $5.62 (372 GBX) price target on the stock.

A number of other firms have also recently commented on AML. Analysts at Barclays Capital reiterated an “overweight” rating on shares of Amlin in a research note to investors on Monday, January 14th. They now have a $7.90 price target on the stock. Separately, analysts at Nomura reiterated a “neutral” rating on shares of Amlin in a research note to investors on Thursday, January 3rd. They now have a $6.85 price target on the stock. Finally, analysts at JPMorgan Chase reiterated an “underweight” rating on shares of Amlin in a research note to investors on Thursday, December 20th. They now have a $5.85 price target on the stock.

Amlin traded up 0.26% on Monday, hitting GBX 425.90. Amlin has a 52-week low of GBX 307.80 and a 52-week high of GBX 419.30. The stock’s 50-day moving average is currently GBX 395.2. The company’s market cap is £2.107 billion.

Amlin plc is engaged in non-life insurance and reinsurance underwriting in the Lloyd’s market, Bermuda and Continental Europe.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.